Leigh Syndrome Treatment Market Research Report: By Diagnosis (MRI, CT, and Laboratory Test), By Treatment (Medications, Medical Procedure, and Surgery), By End User (Hospital, Research Organizations and Academic Institutes) – Global Forecast till 2027

Market Highlights

Leigh’s disease is a progressive neurometabolic disorder occurring often after a viral infection during childhood, however, it can also occur in teens and adults. It is usually diagnosed with the help of MRI of the brain, particularly of the midbrain and brainstem part. The child often appears normal at birth but symptoms begin to appear within a few months to a period of two years of age. These may be accompanied by other problems such as irritability, loss of appetite, vomiting, and seizures. Eventually, the child may also have heart, kidney, vision, and breathing complications. There are different forms of Leigh's disease, but all forms have a poor prognosis. Those with partial deficiencies have a better prognosis but may live to be 6 or 7 years of age. Most cases are fatal during childhood, although some individuals have survived to adolescence.

The most common underlying cause is a defect in energy production in the brain. Inborn errors of metabolism have also been reported with Leigh syndrome. According to researchers the classical form of Leigh syndrome accounted for approximately 80 percent of cases. The prevalence of Leigh syndrome has been estimated at 1 in every 36,000-40,000 births.

get free sample copy @ https://www.marketresearchfuture.com/sample_request/5249

Regional Analysis

Global Leigh Syndrome Treatment Market consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East.

The Americas dominated the global Leigh syndrome treatment market owing to the rising incidences of genetic disorders. The European market holds the second largest share of the global Leigh syndrome treatment market owing to the high prevalence rate of this disease in the Eastern European regions. The Asia Pacific is expected to be the fastest growing region and is anticipated to compete with the American market during the forecasted period 2017-2023. The Middle East & African market especially, the African region is expected to witness a poor growth owing to the lack of knowledge in the medical sector, and less development in medical facilities in the Middle East & Africa will have limited growth in the market.


Key Players

Some of key the players in the global Leigh syndrome treatment market are GlaxoSmithKline Plc (GSK), Brother Enterprises (China), Huazhong Pharma (China), Zhejiang Tianxin (China), Stryker Corporation (U.S.), Zimmer Biomet Holdings, Inc. (U.S.), Wright Medical Technology, Inc. (U.S.), Integra LifeSciences Holdings Corporation (U.S.), and others.

Browse Full Report @ https://www.marketresearchfuture.com/reports/leigh-syndrome-treatment-market-5249 .

Related reports

Global Epilepsy Devices Market Research Report—Forecast till 2027

Global Artificial Insemination Market Research Report—Forecast till 2027

Global Ear Infection Treatment Market Research Report—Forecast till 2027

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:

Market Research Future